卡维地洛对充血性心力衰竭临床疗效与安全性分析被引量：2

导出

摘要目的探讨卡维地洛对心衰患者心功能的疗效与安全性分析。方法90例充血性心力衰竭(CHF)患者随机分为治疗组和对照组各45例,2组患者均使用血管紧张素转换酶抑制剂、利尿剂和硝酸酯类药物,治疗组在此基础上给予卡维地洛口服3.125mg,2次/d,剂量每周加倍递增,直至病人不能耐受或达最大剂40mg/d。结果治疗组总有效率91.11%,对照组总有效率77.78%(P<0.05)。2组治疗后LVESD、LVEDD和LVEF均明显改善(P<0.05或P<0.01),组间比较,治疗组疗效优于对照组(P<0.05)。结论卡维地络对充血性心力衰竭疗效确切,安全性高。

作者叶新源

机构地区广东省河源市龙川县人民医院内科

出处《中外医疗》 2010年第2期100-101,共2页 China & Foreign Medical Treatment

关键词卡维地洛心力衰竭临床疗效安全性

分类号 R711.32 [医药卫生—妇产科学]

引文网络
相关文献

参考文献8

1Packer M. The neurohumoral hypothesia theory to explain the mechanism of disease progression in heart failure[J].J An Coll Cardiol, 1992,20:248 - 254.
2Hunt SA,Baker DW,Chin MH,et al.ACC/AHA guidelines for the e valuation and management of chronic heart failure in the adult:ex ecutive summary.A report of the ACC/AHA task force on practic e guidelines[J].J Am Coll Cardiol,2001,35:2101 - 2113.
3慢性收缩性心力衰竭治疗建议[J].中华心血管病杂志,2002,30(1):7-23. 被引量：2411
4穆晓光,翟爱芳,王雪芹,涂涛田.卡维地洛治疗慢性充血性心力衰竭的疗效观察[J].中西医结合心脑血管病杂志,2007,5(10):995-995. 被引量：5
5王频佳,王娴.生物标志物—血清脑钠素在充血性心力衰竭诊断中的价值(英文)[J].成都医学院学报,2007,2(Z1):174-176. 被引量：6
6胡大一,吴彦.竭的现代治疗[M].天津:天津科学技术出版社,2003:208-210.
7吴学思.慢性心力衰竭的药物治疗进展[J].继续医学教育,2006,20(1):43-46. 被引量：10
8段东杰,王绍欣,王宏运.卡维地洛治疗慢性心力衰竭疗效观察[J].临床荟萃,2007,22(15):1115-1117. 被引量：7

二级参考文献25

1胡大一马长生.心脏病学实践[M].北京:人民卫生出版社,2003.23-31.
2Urrutia A,Lupon J,Altimir S,et al.Use of beta blockers in elderly patients with congestive heart failure[J].Med Clin Clinica,2006,126(6):206-210.
3Okamoto H,Tsutsui H,Kitabatake A.Future perspectives of beta-blockers in chronic heart failure[J].Nippon Rinsho,2006,64(5):921-926.
4Castro P,Vukasovic JL,Chiong M,et al.Effects of carvedilol on oxidative stress and chronotropic response to exercise in patients with chronic heart failure[J].Eur J Heart Fail.2005,7(6):1033-1039.
5Macdonald PS,Hill J,Krum H.et al.The impact of baseline HR and BP on the tolerability of carvedilol in the elderly:the COLA (Carvedilol Open Label Assessment) II Study[J].Am J Cardiovasc Drug,2006,6(6):401-405.
6Krum H,Hill J,Fruhwald F,et al.Tolerability of beta-blockers in elderly patients with chronic heart failure:the COLA II study[J].Eur J Heart Fail,2006,8(3):302-307.
7Greenway SC,Benson LN.The use of carvedilol in pediatric heart failure[J].Cardiovasc Hematol Disord Target,2006,6(1):35-42.
8Castro PF,Mc-Nab P,Quintana JC,et al.Effects of carvedilol upon intra-and interventricular synchrony in patients with chronic heart failure[J].Am J Cardiol,2005,96(2):267-269.
9Doughty RN,White HD.Carvedilol:use in chronic heart failure[J].Expert Rev Caediovasc Ther,2007,5(1):21-31.
10Kawashiro N,Matsuda N,Endo Y,et al.Long-term outcome and tolerability of carvedilol therapy in Japanese patients with chronic heart failure[J].J Cardiol,2006,47(5):229-237.